Literature DB >> 21277328

Activated T cells induce rapid CD83 expression on B cells by engagement of CD40.

Birte Kretschmer1, Svenja Kühl, Bernhard Fleischer, Minka Breloer.   

Abstract

The conserved transmembrane glycoprotein CD83 was originally described as highly specific marker for mature dendritic cells in the peripheral circulation. Besides its regulatory role in thymic T cell maturation and peripheral T cell activation, recent studies suggest, that CD83 is also involved in the regulation of B cell maturation, homeostasis and function. Here we show, that antigen-specific T cell stimulation leads to CD83 induction predominantly on B cells. In vivo activation of T cells by injection of cognate antigenic peptide into T cell receptor transgenic mice induced strong expression of the early activation marker CD69 but only low levels of surface CD83 on T cells. In contrast CD83 was induced on 80% of B cells in the draining lymph node. This T cell mediated induction of CD83 expression on B cells was not mediated by soluble factors but was contact dependent because separation of B cells from an ongoing T cell stimulation in a transwell system abrogated CD83 expression. Since CD83 expression was induced on both MHC-matched and MHC-mismatched B cells present in cultures of activated T cells, cell contact via TCR/MHC binding was not essential. The application of an antibody to the CD40 ligand of T cells, however, strongly interfered with the induction of CD83 expression on bystander B cells. Taken together we provide evidence that activated T cells induce CD83 on B cells via CD40 engagement but independent of TCR/MHC binding and thus independent of antigen-specificity of B cells.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277328     DOI: 10.1016/j.imlet.2011.01.013

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  16 in total

Review 1.  Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Authors:  Richard S Kornbluth; Mariusz Stempniak; Geoffrey W Stone
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

2.  Monitoring T cell-dendritic cell interactions in vivo by intercellular enzymatic labelling.

Authors:  Giulia Pasqual; Aleksey Chudnovskiy; Jeroen M J Tas; Marianna Agudelo; Lawrence D Schweitzer; Ang Cui; Nir Hacohen; Gabriel D Victora
Journal:  Nature       Date:  2018-01-17       Impact factor: 49.962

3.  Epithelial cell-derived CD83 restores immune tolerance in the airway mucosa by inducing regulatory T-cell differentiation.

Authors:  Li-Hua Mo; Xiang-Qian Luo; Gui Yang; Jiang-Qi Liu; Li-Teng Yang; Zhi-Qiang Liu; Shuai Wang; Da-Bo Liu; Zhi-Gang Liu; Ping-Chang Yang
Journal:  Immunology       Date:  2021-02-28       Impact factor: 7.215

4.  Continuous expression of CD83 on activated human CD4⁺ T cells is correlated with their differentiation into induced regulatory T cells.

Authors:  Liwen Chen; Shihe Guan; Qiang Zhou; Shouqin Sheng; Fei Zhong; Qin Wang
Journal:  Mol Med Rep       Date:  2015-05-18       Impact factor: 2.952

5.  Targeting CD83 for the treatment of graft-versus-host disease.

Authors:  Xiongfei Wang; Ming Q Wei; Xiaosong Liu
Journal:  Exp Ther Med       Date:  2013-04-02       Impact factor: 2.447

6.  Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer.

Authors:  Mayu O Frank; Julia Kaufman; Salina Parveen; Nathalie E Blachère; Dana E Orange; Robert B Darnell
Journal:  J Transl Med       Date:  2014-12-05       Impact factor: 5.531

7.  A Kinetic Study of CD83 Reveals an Upregulation and Higher Production of sCD83 in Lymphocytes from Pregnant Mice.

Authors:  Katrin Regina Helene Packhäuser; Gleyder Roman-Sosa; Jens Ehrhardt; Diana Krüger; Marek Zygmunt; Damián Oscar Muzzio
Journal:  Front Immunol       Date:  2017-04-26       Impact factor: 7.561

8.  Characterization of Gene Expression Signatures for the Identification of Cellular Heterogeneity in the Developing Mammary Gland.

Authors:  Samantha Henry; Marygrace C Trousdell; Samantha L Cyrill; Yixin Zhao; Mary J Feigman; Julia M Bouhuis; Dominik A Aylard; Adam Siepel; Camila O Dos Santos
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-05-14       Impact factor: 2.673

9.  Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Rikke Ratzer; Fredrik Piehl; Mohsen Khademi; Tomas Olsson; Per Soelberg Sørensen; Finn Sellebjerg
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

10.  Activated peritoneal cavity B-1a cells possess regulatory B cell properties.

Authors:  Bram Margry; Saskia C W Kersemakers; Aad Hoek; Ger J A Arkesteijn; Willemien H Wieland; Willem van Eden; Femke Broere
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.